dr. Auke Beishuizen

Medicine and Dentistry

1. Acute B-Cell Lymphoblastic Leukemia 13%
2. Adolescent 54%
3. Adult 17%
4. Assessment 16%
5. B Cell 44%
6. Brentuximab Vedotin 13%
7. Cancer 17%
8. Chemotherapy 19%
9. Child 79%
10. Childhood 32%
11. Classical Hodgkin Lymphoma 74%
12. Cohort Analysis 13%
13. Diagnosis 33%
14. Differentiation 13%
15. Diseases 28%
16. Doxorubicin 15%
17. Etoposide 29%
18. Event Free Survival 17%
19. Fluorodeoxyglucose F 18 14%
20. Group Therapy 17%
21. Hodgkin's Lymphoma 68%
22. Incidence 16%
23. Langerhans Cell Histiocytosis 13%
24. Leukemia 14%
25. Logistic Regression Analysis 13%
26. Lymphoblastic Lymphoma 21%
27. Lymphoma 34%
28. Nivolumab 13%
29. Non-Hodgkin Lymphoma 25%
30. Non-Hodgkin Lymphoma in Children 27%
31. Patient 100%
32. Pediatrics 90%
33. Pediatrics Patient 20%
34. Plasma 17%
35. Positron Emission Tomography-Computed Tomography 15%
36. Precursor 32%
37. Prednisone 25%
38. Radiation Therapy 31%
39. Rebound 13%
40. Relapse 15%
41. Rituximab 13%
42. Survival 17%
43. Therapeutic Procedure 56%
44. Thymus and Activation Regulated Chemokine 32%
45. Thymus Hyperplasia 13%
46. Titrimetry 27%
47. Treatment Response 15%
48. Vincristine 39%
49. Waldeyer Ring 13%
50. Young Adult 41%